Rapport Therapeutics Inc.... (RAPP)
NASDAQ: RAPP
· Real-Time Price · USD
14.66
-0.11 (-0.74%)
At close: Aug 25, 2025, 12:02 PM
Rapport Therapeutics Common Stock Income Statement
Financials in USD. Fiscal
year is
undefined.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
Revenue | 720K | 720K | 720K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 715K | 671K | 579K | 655K | 436K | 249K | 112K | 36K | 36K | 15K |
Gross Profit | -355K | -311K | -219K | -655K | -436K | -249K | -112K | -36K | -36K | -15K |
Operating Income | -101.77M | -93.07M | -83.06M | -74.33M | -62.25M | -48.08M | -36.18M | -21.39M | -11.82M | -5.19M |
Interest Income | 13.45M | 13.37M | 12.14M | 9.97M | 6.72M | 4.27M | 2.53M | 1.15M | 296K | 75K |
Pretax Income | -88.31M | -79.7M | -78.31M | -71.84M | -63.01M | -51.3M | -34.78M | -21.26M | -12.55M | -6.15M |
Net Income | -88.31M | -79.7M | -78.31M | -71.85M | -63.02M | -51.31M | -34.79M | -21.27M | -12.56M | -6.15M |
Selling & General & Admin | 26.77M | 24.86M | 21.76M | 18.36M | 14.24M | 11.23M | 8.07M | 5.15M | 3.17M | 1.28M |
Research & Development | 74.99M | 68M | 60.94M | 55.53M | 47.57M | 36.6M | 28M | 16.2M | 8.62M | 3.9M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 101.77M | 92.86M | 82.69M | 73.89M | 61.82M | 47.83M | 36.07M | 21.35M | 11.79M | 5.18M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | -208K | -360K | -436K | -436K | -249K | -112K | -36K | -36K | -15K |
Cost & Expenses | 101.77M | 93.07M | 83.06M | 74.33M | 62.25M | 48.08M | 36.18M | 21.39M | 11.82M | 5.19M |
Income Tax Expense | n/a | n/a | n/a | 6K | 7K | 9K | 10K | 4K | 3K | 1K |
Shares Outstanding (Basic) | 354.45M | 192.88M | 192.88M | 191.71M | 201.17M | 194.57M | 180.79M | 190.98M | 201.17M | 194.57M |
Shares Outstanding (Diluted) | 354.45M | 192.88M | 192.88M | 191.71M | 201.17M | 194.57M | 180.79M | 190.98M | 201.17M | 194.57M |
EPS (Basic) | -1.06 | -0.4 | -0.4 | -0.38 | -0.33 | -0.27 | -0.18 | -0.11 | -0.06 | -0.03 |
EPS (Diluted) | -1.06 | -0.4 | -0.4 | -0.38 | -0.33 | -0.27 | -0.18 | -0.11 | -0.06 | -0.03 |
EBITDA | -101.29M | -92.38M | -82.22M | -72.29M | -60.41M | -46.43M | -34.66M | -21.33M | -11.79M | -5.18M |
EBIT | -95.96M | -90.02M | -83.06M | -72.92M | -60.85M | -46.68M | -34.78M | -21.39M | -11.82M | -5.19M |
Depreciation & Amortization | 723K | 931K | 839K | 632K | 436K | 249K | 112K | 59K | 36K | 15K |